精神分裂症攻击行为与儿茶酚氧位甲基转移酶基因多态性

目的研究中国昆明地区汉族人群儿茶酚氧位甲基转移酶(COMT)基因Val158Met多态性与精神分裂症攻击行为的相关性。方法采用外显攻击行为量表(OAS)测量88例符合美国精神障碍诊断与统计手册第4版(DSMⅣ)和中国精神障碍分类与诊断标准第3版(CCMD3)的精神分裂症患者;并应用聚合酶链反应(PCR)-限制性片段长度多态性(RFLP)的方法检测他们的COMT基因多态性。结果攻击行为患者与无攻击行为患者各基因型及基因型频数分布无显著差异;但分性别后发现:有攻击行为男性患者与无攻击行为男性患者等位基因频率比较有显著性差异(P<0.05),将158Met作为危险因素,OR值等于4.55,95%CI为1.36～15.19。而有、无攻击行为的女性患者间的等位基因频数比较无显著差异(P>0.05)。结论COMTVal158Met基因多态性与精神分裂症的攻击性行为有关,中国昆明地区的男性患者的低活性等位基因与攻击性行为显著相关联。     

五羟色胺2C受体基因多态性与抗精神病药急性期治疗精神分裂症疗效关系初探

目的 研究五羟色胺2C受体(5HTR2C)基因启动子区功能多态性与首次治疗的精神分裂症患者精神症状严重程度及抗精神病药物(APS)急性期治疗疗效相关性。方法 采用PCR-RFLP方法分析109例首次治疗精神分裂症患者(男53例,女56例)5HTR2C基因启动区-759C/T单核酸置换多态性;临床用阳性和阴性症状量表(PANSS)评定患者治疗前后精神症状,分析单体型(男性)或暴因型(女性)和其他临床指标与治疗前PANSS分值和治疗后PANSS减分率的相关性。结果5HTR2C基因-759C/T基因型在女性患者组的分布频率符合H-W定律(P>0.05);-759T单体型(男性)或携带-759T的基因型(女性)在治疗显效组和治疗未显著进步组分布频率无显著性差异;单体型或基因型亚组的临床指标均无显著性差异;-759C/T对首次治疗精神分裂症患者PANSS分值无显著影响,但对治疗10周后PANSS总减分率和阴性症状减分率有显著影响。结论 5HTR2C基因启动子区-759C/T单核酸置换多态性在APS急性期治疗疗效中,可能主要影响对阴性症状的控制。     

5-羟色胺2A受体基因多态性与利培酮治疗中国首发精神分裂症患者疗效关联

背景5-羟色胺2A受体基因已经证实为精神分裂症的候选易感基因,因为阐明其作为非典型抗精神病药物重要作用靶点减轻阴性症状已引起业界倍加关注.本研究试图探讨(1)5-HT2A受体基因T102C多态性在不同临床亚型之间等位基因和基因型频率的关系,(2)5-HT2A受体基因T102C在利培酮高剂量组和低剂量组之间基因型和等位基因分布频率的关系,(3)5-HT2A受体基因T102C多态性在治疗有效组与无效组之间的基因型和等位基因分布频率的关系,(4)5-羟色胺2A受体T102C基因多态性是否与中国首发精神分裂症患者利培酮疗效有关.方法对201例精神分裂症初发期患者分别进行利培酮治疗[3～5 mg/d,平均(3.2±1.3)mg/d],疗程8周.采用聚合酶链式反应扩增与限制性片段长度多态性(PCR-RFLP)技术检测5-HT2A受体基因T102C多态性.以临床亚型将精神分裂症患者划分为偏执型、瓦解型、未定型和其他型,分析不同临床亚型等位基因和基因型频率的差异;按服用利培酮剂量划分低剂量组(＜4 mg/d)和高剂量组(≥4 mg/d),经比较利培酮高剂量组和低剂量组的5-HT2A受体基因T102C基因型和等位基因分布频率差异性;同时以阴性和阳性症状量表(PANSS)总减分率＞50%有效,≤50%为无效以分析治疗有效组与无效组之间的基因型和等位基因分布频率差异有无显著性;以PANSS评定患者治疗前及治疗后2周、4周、6周和第8周末的精神症状,比较5-HT2A受体T102C各基因亚型与年龄、发病年龄、PANSS总分值、阳性症状基线分、阴性症状基线分、一般病理症状基线分、PANSS总减分率、阳性症状减分率、阴性症状减分率和一般病理症状减分率的差异.结果5-HT2A受体T102C基因型在患者组分布频率均符合H-W平衡定律(P＞0.05);不同临床诊断亚型精神分裂症患者等位基因和基因型频率无显著性差异(χ2=0.415,P=0.937;χ2=1.705,P=0.941);高剂量组与低剂量组之间的基因型和等位基因分布频率差异均无显著性(χ2=2.402,P=0.301;χ2=2.465,P=0.116);治疗有效和无效组的基因型和等位基因分布频率的差异无显著性(χ2=1.995,P=0.369;χ2=1.939,P=0.164);各基因型亚组的年龄、发病年龄及其病程差异均无显著性(P均大于0.05);但基因亚组A1/A1的治疗前PANSS总分(χ2=4.076,P=0.018)和阴性症状分(χ2=3.946,P=0.021)以及治疗结束PANSS总分减分率(χ2=4.036,P=0.019)和阴性症状减分率(χ2=3.876,P=0.022)均显著高于A1/A2及A2/A2基因型.结论(1)首发精神分裂症患者不同临床亚型5-HT2A受体基因T102C基因型和等位基因频率无显著差异.(2)利培酮高剂量组和低剂量组5-HT2A受体基因T102C基因型和等位基因分布频率没有显著性差异.(3)治疗有效组与无效组之间5-HT2A受体基因T102C基因型和等位基因分布频率也无显著性差异.(4)5-HT2A受体T102C Ai/A1基因亚型可能影响中国首发精神分裂症患者对利培酮的治疗效应.     

COMT基因多态性与慢性精神分裂症患者认知功能的相关性研究

目的:探讨上海汉族人口中儿茶酚胺氧位甲基转移酶(COMT)基因Val108/158Met多态性与慢性精神分裂症患者认知功能的关系。方法:采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术对152例慢性精神分裂症患者COMT基因多态性进行检测,并选用连线测验(TMT)、韦氏记忆测验(WMS)、威斯康星卡片分类测验(WCST)对其认知功能进行评定。结果:COMT基因与TMT成绩显著相关,其中高活性G/G基因型患者B部分成绩显著低于低活性A/A基因型患者。COMT基因与WMS成绩显著相关,其中G/G基因型患者记忆商数分、背数分显著低于A/A基因型患者。COMT基因与WCST成绩无显著相关性。结论:COMT基因与慢性精神分裂症患者认知功能具有显著相关性,其中高活性G/G基因型患者认知损害更明显。     

多巴胺D3受体基因多态性与精神分裂症初发期患者抗精神病药疗效关系的研究

目的　探讨多巴胺D3 受体 (DRD3)基因多态性与精神分裂症初发期患者精神症状严重度和抗精神病药疗效是否相关。方法　对 10 9例精神分裂症初发期患者分别进行利培酮治疗 [4 3例 ,3～ 5mg/d ,平均 ( 4 0± 0 5 )mg/d]和氯丙嗪治疗 [6 6例 ,15 0～ 6 0 0mg/d ,平均 ( 339± 87)mg/d],疗程 10周。采用聚合酶链反应 限制性片段长度多态性技术检测其中 10 8例患者 (男 5 2例 ,女 5 6例 )DRD3基因ser9gly多态性。采用阳性和阴性症状量表 (PANSS)评定患者治疗前和治疗第 10周末的精神症状 ,并分析基因型及其他临床指标与PANSS分值和减分率的关系。结果　DRD3ser9gly基因型在各患者组分布频率均符合Hardy Weinberg定律 (P >0 0 5 ) ;基因型在治疗显效和未显著进步组分布频率的差异有显著性 ( χ2 =6 4 4 ,ν=2 ,P <0 0 5 ) ;各基因型亚组临床指标的差异均无显著性 (均P >0 0 5 ) ;基因型与患者治疗前PANSS总分及治疗第 10周末PANSS总减分率、阳性症状减分率的差异均有显著性(均P <0 0 5 )。结论　DRD3基因ser9gly功能多态性可能是精神分裂症初发期患者精神症状严重程度和抗精神病药疗效 (尤其对阳性症状疗效 )的遗传影响因子。     

精神分裂症与儿茶酚邻位甲基转移酶基因多态性的关联分析

目的：探讨精神分裂症与儿茶酚邻位甲基转移酶（COMT）基因Val158Met多态性的关系。方法：采用聚合酶链反应技术检测符合诊断 标准的476例精神分裂症患者（病例组）和207例名正常对照者（对照组）的COMT基因Val158Met多态性，并进行关联分析，结果：（1）病例组与对照组基因型及等位基因分布频率的差异无显著性（P＞0．05）；（2）首次起病以阳性症状为主的患者Val158Val基因型（56．5％）高于非阳性症状为主型者（45．5％；P＝0．07）；（3）在男性患者中，不吸烟患者的Met 158Met基因型分布频率（11．9％）高于吸烟患者（4．1％；P＜0．05），OR＝3．137）；两者等基因分布的差异无显著性（P＞0．05）。结论：COMT基因多态性可能与精神分裂症某些临床特点存在关联。     

精神分裂症患者茶酚氧位甲基转移酶基因多态性与利培酮疗效的关系

目的:探讨精神分裂症患者茶酚氧位甲基转移酶(COMT)基因多态性与利培酮疗效的关系。方法:95例精神分裂症患者(患者组)接受利培酮单药治疗12周,治疗前后给予阳性与阴性症状量表(PANSS)、瞬时记忆测评、数字划消测验、瑞文标准推理测试;对患者及95名健康对照者(对照组)进行COMT基因的rs4680、rs165599、rs6267和rs4818位点的多态性分析,比较各基因型患者利培酮治疗后各量表评分的变化。结果:两组间COMT rs4680位点各基因型和等位基因频率、rs4680-rs165599 AG型单倍体频率差异有统计学意义(P0.05或P0.01);治疗前后患者PANSS阴性症状因子评分的变化值在rs4680位点各基因型间比较差异有统计学意义(t=2.383,P=0.019);瞬时记忆测评的变化值在rs165599位点的各基因型间差异有统计学意义(F=4.213,P=0.019);PANSS阴性症状因子、认知损害因子以及瞬时记忆测评的变化值在rs6267位点各基因型间差异有统计学意义(F=4.978,3.495,6.086;P均0.01);PANSS认知损害因子的变化值在rs4818位点的各基因型间差异有统计学意义(F=4.251;P=0.014)。结论:COMT rs4680-rs165599 AG型单倍体携带者可能具有精神分裂症患病风险,COMT基因多态性在一定程度上影响精神分裂症患者利培酮的疗效及认知功能。     

儿茶酚氧位甲基转移酶基因多态性与焦虑症的相关性研究

目的 探讨儿茶酚氧位甲基转移酶(COMT)Val108/158Met基因多态性与焦虑症之间的关系.方法 采用聚合酶链反应一限制性片段长度多态性方法检测了176例焦虑症患者(患者组)和200名健康体检者(对照组)COMT Val108/158Met位点基因型,分析基因型和等位基因频率在2组间的分布差异,及其与患者临床症状表型之间的关系.患者均经汉密尔顿焦虑量表(HAMA)和症状自评定量表测评.结果 (1)患者组COMT 108/158Met/Met基因型和Met等位基因频率的分布为6.25%、26.99%,对照组为2.50%、18.75%,2组比较差异均有统计学意义(P均<0.05);患者组女性COMT 108/158Met/Met基因型和Met等位基因频率的分布高于对照组女性,2组比较差异有统计学意义(P<0.05);患者组男性COMT 108/158Met/Met基因型和Met等位基因频率的分布与对照组男性比较,差异无统计学意义(P>0.05).(2)患者组内COMT 108/158Met/Met基因型和携带Met等位基因患者HAMA总分、焦虑和恐怖因子分值分别高于其他基因型和携带Val等位基因患者(P均<0.05).结论 携带COMT Met108/158女性可能更易患焦虑症,COMT Met108/158与临床焦虑和恐怖程度有关.

Abstract：

Objective To explore the relationship of the Val108/158Met polymorphism of Catechol-O-methyl transferase(COMT)gene and anxiety in Han population.Methods The COMT Val108/158Metpolymorphism was detected by polymerase chain reaction-restriction fragment length polymorphism(PCRRFLP)among 176 patients and 200 health subjects.The clinical symptom phenotypes data were obtained by assessing the HAMA and SCL-90 in anxiety patients.Results The distribution frequencies of Met/Met genotype and Met allele were 6.25%.2.50%and 26.99%.18.75%in patients and controls,respectively.Both distribution frequencies were significantly different in two groups,especially in females (P<0.05),and no significant difference was in males between two groups(P>0.05).Following analyzing the clinical symptom phenotypes,the patients with COMT 108/158Met/Met genotype or Met allelic locus had higher HAMA,SCL-90 anxiety and phobic scores than those with other genotypes or Val allelic locus (P<0.05).Conclusion The female individuals with COMT Met108/158 polymorphism may have higher susceptibility to anxiety,and be associated with clinical symptom phenotypes of anxiety.     

精神分裂症患者多巴胺D2受体基因多态性与利培酮治疗效应的关联分析

目的:探讨多巴胺D_2受体基因(DRD2)多态性与利培酮治疗精神分裂症临床疗效的关系。方法:纳入汉族精神分裂症患者304例(研究组)和汉族健康对照120名(对照组),研究组服用利培酮8周后以阳性与阴性症状量表(PANSS)评估疗效,同时检测两组DRD2基因rs6275、rs1801028和rs6277位点多态性。结果:rs6277位点在研究组和对照组中的等位基因频率与基因型频率的分布差异有统计学意义(χ~2=8.37,P=0.02)。研究组rs6275(F=15.52,P0.001)、rs1801028(F=19.74,P0.001)和rs6277(F=10.67,P0.001)位点不同基因型在PANSS总分减分率上差异均有统计学意义;同时rs1801028位点不同基因型在阴性症状减分率上差异有统计学意义(F=15.29,P0.001),rs6277位点在阳性症状减分率上差异有统计学意义(F=14.74,P0.001)。结论:DRD2基因rs6277位点多态性与精神分裂症易感性存在关联;不同DRD2基因型患者利培酮疗效可能存在差异。     

天津地区汉族人群COMT基因多态性与脑梗死相关性研究

研究背景儿茶酚胺氧位甲基转移酶(COMT)是儿茶酚胺的主要代谢酶,催化儿茶酚胺第3位羟基甲基化,降解儿茶酚胺,同时亦是雌激素的主要代谢酶。COMT基因在rs4680位点存在鸟嘌呤腺嘌呤(G-A)点突变,使其编码的第108和(或)158位氨基酸由缬氨酸(Val)变为蛋氨酸(Met),导致儿茶酚胺氧位甲基转移酶活性降低。已知COMT基因多态性与精神疾病、酒精依赖、药物不良反应等有关,而与脑梗死之间的关系尚不明确,本研究旨在探讨COMT基因多态性与脑梗死之间的关系。方法通过聚合酶链反应限制性酶切片段长度多态性方法检测181例天津地区汉族脑梗死患者COMT Val及Met基因型,以及不同基因型脑梗死患者血糖、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇,以及载脂蛋白A和B水平。结果脑梗死组Val等位基因频率(78.45%)及Val/Val纯合子基因型(61.33%)均高于正常对照组(68.24%和45.95%),差异具有统计学意义(P<0.05);进一步分析显示男性Val等位基因频率(82.52%)与正常对照组(66.67%)之间差异亦存在统计学意义(P<0.01),而女性患者组间差异(69.83%对69.07%)无统计学意义(P>0.05)。脑梗死组Val/Val型与Val/Met+Met/Met型比较,血糖、血脂水平及高血压患病率差异无统计学意义(均P>0.05)。结论 COMT Val等位基因频率和Val/Val纯合子基因型是男性脑梗死患者的遗传学危险因素,COMT对脑梗死的影响与血糖、血脂及血压无明显相关性。     

Sensorimotor gating of schizophrenia patients depends on Catechol O-methyltransferase Val158Met polymorphism

It has been recently shown that Catechol O-methyltransferase (COMT) Val(158)Met polymorphism strongly influences prepulse inhibition (PPI) of the acoustic startle response (ASR) in healthy human volunteers. Given that schizophrenia patients exhibit impairment in PPI and that COMT is a putative susceptibility gene for schizophrenia, we investigated the impact of the COMT Val(158)Met polymorphisms on PPI in schizophrenic inpatients. We analyzed COMT Val(158)Met polymorphisms and assessed startle reactivity, habituation, and PPI of ASR in 68 Caucasian schizophrenia inpatients. Clinical symptoms were measured with the Positive and Negative Syndrome Scale (PANSS). Patients carrying the Val(158)Met Met/Met allele showed elevated PPI levels whereas startle reactivity and habituation did not differ from the other two genotypes. These preliminary results imply that PPI is influenced by COMT Val(158)Met genotype in schizophrenia as well. In concert with other findings, our data suggest that PPI is a polygenic trait.     

中国南方汉族人群CYBA基因C242T多态性与精神分裂症的关联

目的 探讨中国南方汉族人群NADPH氧化酶p22phox亚基基因(CYBA)C242T多态性和精神分裂症的易感性及疾病严重程度的关联.方法 本研究利用SNaPshot技术对906例中国南方汉族人群精神分裂症患者和982名健康对照者进行CYBA基因C242T多态性检测,采用阳性与阴性症状量表(PANSS)对患者组进行精神症状严重程度评定.结果 (1)CYBA基因C242T多态性位点基因型频率和等位基因频率在精神分裂症患者和健康人群中的分布差异无统计学意义(P>0.05);(2)C242T多态性位点CT+TT基因型患者PANSS量表的阴性量表分及总分高于CC基因型患者(P<0.05).结论 CYBA基因C242T多态性与中国南方汉族精神分裂症的易感性无明显关联,C242T多态性位点T突变可能会加重精神分裂症患者的阴性症状.     

Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia

OBJECTIVE: Deficits in working memory and in prefrontal cortical physiology are important outcome measures in schizophrenia, and both have been associated with dopamine dysregulation and with a functional polymorphism (Val(108/158)Met) in the catechol O-methyltransferase (COMT) gene that affects dopamine inactivation in the prefrontal cortex. The purpose of the present study was to evaluate in patients with schizophrenia the effect of COMT genotype on symptom variation, working memory performance, and prefrontal cortical physiology in response to treatment with an atypical antipsychotic drug. METHOD: Thirty patients with acute untreated schizophrenia were clinically evaluated with the Positive and Negative Syndrome Scale, underwent COMT Val/Met genotyping, and entered an 8-week prospective study of olanzapine treatment. Twenty patients completed two 3-T functional magnetic resonance imaging scans at 4 and 8 weeks during performance of N-back working memory tasks. RESULTS: There was a significant interaction of COMT genotype and the effects of olanzapine on prefrontal cortical function. Met allele load predicted improvement in working memory performance and prefrontal physiology after 8 weeks of treatment. A similar effect was found also for negative symptoms assessed with the Positive and Negative Syndrome Scale. CONCLUSIONS: These results suggest that a genetically determined variation in prefrontal dopamine catabolism impacts the therapeutic profile of olanzapine.     

COMT Val158Met-stress interaction in psychosis: role of background psychosis risk

Background: The interplay between the catechol‐O‐methyltransferase (COMT) Val158Met polymorphism and environmental stress may have etiological relevance for psychosis, but differential effects have been reported in healthy control and patient groups, suggesting that COMT Val158Met interactions with stress may be conditional on background genetic risk for psychotic disorder. Methods: Patients with a nonaffective psychotic disorder (n = 86) and control participants (n = 109) were studied with the experience sampling method (a structured diary technique) in order to assess stress, negative affect and momentary psychotic symptoms in the flow of daily life. Results: Multilevel analyses revealed significant three‐way interactions between group status (patient or control), COMT genotype and stress in the model of negative affect (χ²(2) = 13.26, P < 0.01) as well as in the model of momentary psychotic symptoms (χ²(2) = 6.92, P < 0.05). Exploration of the three‐way interaction revealed that in patients, COMT genotype moderated the association between stress and negative affect (χ²(4) = 11.50, P < 0.005), as well as the association between stress and momentary psychosis (χ²(4) = 12.79, P < 0.005). Met/Met genotype patients showed significantly increased psychotic and affective reactivity to stress in comparison to the Val/Met and Val/Val genotypes. In contrast, healthy controls did not display large or significant COMT Val158Met X stress interactions. Conclusions: Important differences exist in the effect of COMT Val158Met on stress reactivity, which may depend on background risk for psychotic disorder. Differential sensitivity to environmental stress occasioned by COMT Val158Met may be contingent on higher order interactions with genetic variation underlying psychotic disorder.     

Eye movement disturbances in schizophrenia and a polymorphism of catechol-O-methyltransferase gene

Previous studies suggested an association between the catechol-O-methyltransferase (COMT) Val/Met polymorphism and the performance on neuropsychological tests, measuring prefrontal function in schizophrenia. The aim of this study was to examine the relationship between this polymorphism and performance on oculomotoric tests in schizophrenic patients. The intensity of eye movement disturbances on fixation and smooth pursuit tests and the Val/Met polymorphism of COMT gene were studied in 117 schizophrenic patients (74 male and 43 female). In male schizophrenic patients, the mean intensity of both kinds of eye movement disturbances was lower in subjects who had the Met/Met genotype, with significant difference compared to other genotypes. Also, a significantly higher frequency of the Met allele and the Met/Met genotype was found in male schizophrenic patients exhibiting a lower intensity of smooth pursuit disturbances, and a trend in this direction was observed for the intensity of fixation disturbances. No such relationship was found in female schizophrenic patients. The results obtained suggest that, in male schizophrenic patients the Met allele of the COMT Val/Met polymorphism may have an alleviating effect on eye movement disturbances. They also point to possible gender differences as to the role of COMT in brain function in schizophrenia.     

COMT基因多态性与迟发性运动障碍的关联研究

目的探讨中国汉族人口中儿茶酚胺氧位甲基转移酶(COMT)基因Val108/158Met多态性与迟发性运动障碍(TD)的关系。方法以124例伴TD的精神分裂症患者(TD组)、112例不伴TD的精神分裂症患者(非TD组)及112例正常健康对照者(正常对照组)为研究对象,并采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术检测COMT基因多态性。结果(1)TD组与非TD组及正常对照组比较,等位基因及基因型频率均无统计学差异。(2)非TD组与正常对照组比较,非TD组的高活性G等位基因频率(0.78)显著高于正常对照组(0.70),低活性A等位基因频率(0.22)显著低于正常对照组(0.30);非TD组低活性A/A基因型频率(0.02)显著低于正常对照组(0.07)。(3)COMT基因型与TD严重程度具有显著相关性,A/A基因型患者的TD严重程度评分显著高于G/G基因型。结论本研究未发现COMT基因与TD的发生有关联。不伴TD的精神分裂症可能与COMT基因存在相关性,高活性G等位基因可能增加了不伴TD的精神分裂症的发生风险。COMT基因型与TD严重程度可能具有相关性,低活性A/A基因型患者可能较高活性G/G基因型患者表现更严重的TD。     

酸性神经酰胺酶基因与精神分裂症症状数量性状的关联研究

目的 探讨酸性神经酰胺酶基因(ASAH1)与精神分裂症症状数量性状的关联.方法 应用聚合酶链反应及限制性片段长度多态性技术,对254例精神分裂症患者ASAH1基因的3个单核苷酸多态性(rs3753118、rs3753116及rs7830490)进行检测;使用阳性和阴性症状量表(PANSS)评定患者疾病表型的数量性状.结果 (1)患者rs3753118位点3种基因型间的阳性症状分的差异有统计学意义(F=3.506,P＜0.05);rs3753116位点3种基因型间的PANSS总分及阴性症状分的差异均有统计学意义(F=3.548,P＜0.05;F=3.358,P＜0.05).经两两比较,rs3753118位点C/C基因型组患者的阳性症状分及一般精神病理分明显高于C/T基因型组患者;rs3753116位点G/G基因型组患者的PANSS总分及阴性症状分明显高于A/G基因型组患者,且G/G基因型组患者的阴性症状分明显高于A/A基因型组患者,差异均有统计学意义(P均＜0.05).(2)患者3个位点各等位基因间的PANSS量表评分的差异无统计学意义(P＞0.05).(3)患者rs3753118C-rs3753116G单体型者及rs3753118C-rs3753116G-rs7830490A单体型者,其PANSS总分及阴性症状分均明显高于参照单体型者,差异均有统计学意义(P均＜0.05).结论 ASAH1基因区域可能存在精神分裂症症状数量性状位点.     

精神分裂症患者儿茶酚胺氧位甲基转移酶基因单核苷酸多态位点与利培酮疗效的关联研究

目的 分析利培酮治疗首次发病(以下简称首发)的精神分裂症患者疗效与儿茶酚胺氧位甲基转移酶(COMT)基因多态性的关联,探讨利培酮疗效的敏感基因.方法 对203例首发精神分裂症患者给予利培酮治疗8周(2～8 ms/d),分别于治疗前和治疗第2～8周末采用阳性和阴性症状量表(PANSS)评分,以减分率评定疗效.并采用限制性片段长度多态技术和序列特异性引物聚合酶链反应技术测定基因型.对痊愈组(29例)、进步组(153例)及无效组(21例)精神分裂症患者与COMT基因单核苷酸多态位点(SNPs)进行关联分析.结果 COMT基因3种多态性基因型及基因频率在利培酮不同疗效患者组间分布差异均无统计学意义(P均＞0.05).COMT的3个单核苷酸多态位点单体型分析,利培酮治疗痊愈组与进步组、有效组与无效组间的差异无统计学意义(P＞0.05).结论 COMT基因可能不是首发精神分裂症患者抗精神病药利培酮的疗效敏感基因.     

Association of the functional polymorphism in the catechol-O-methyltransferase gene with schizophrenia in the three ethnic groups of the Malaysian population

The catechol-O-methyltransferase (COMT) gene is a candidate gene for schizophrenia as its encoded enzyme is involved in the metabolic inactivation of dopamine and noradrenaline. Several molecular genetic studies thus far have demonstrated that the COMT functional polymorphism of Val158Met is susceptible with schizophrenia. Hence, the present study aims to determine this genetic association of this SNP in the three major ethnic groups of the Malaysian population. A total of 317 patients (79 Malays, 154 Chinese and 84 Indians) meeting DSM-IV criteria for schizophrenia and 417 healthy subjects (160 Malays, 164 Chinese and 93 Indians) were recruited. A PCR-RFLP method was used to determine the genotypes and alleles present. We found a significant association of genotypes within the total pooled samples, as well as in the female subgroup, with a higher frequency of heterozygotes in schizophrenia subjects. However, there were no significant differences in allele and genotype frequency between the schizophrenic patients and normal controls in all three ethnic groups. Our current findings suggest that the Val158Met polymorphism has a weak association with schizophrenia in the Malaysian population and does not play a major role in conferring susceptibility to the schizophrenia in any of the three major local ethnicities.     

Catechol-O-methyltransferase gene and obsessive-compulsive symptoms in patients with recent-onset schizophrenia: preliminary results

The catechol-O-methyltransferase (COMT) gene is a candidate gene for schizophrenia because of its role in the breakdown of dopamine in the prefrontal cortex. The COMT gene contains a functional polymorphism changing enzyme activity that has been associated with some neuropsychiatric (endo)phenotypes, e.g. cognitive performance and anxiety. In this study we investigated the association between the COMT Val(158)Met polymorphism and obsessive-compulsive symptoms in patients with schizophrenia. Severity of obsessive-compulsive symptoms in 77 male patients with recent-onset schizophrenia was assessed using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), and the COMT Val(158)Met polymorphism was genotyped for these patients. We found a significant effect of the COMT genotype on Y-BOCS scores: the Val/Val genotype was associated with the highest Y-BOCS scores, whereas patients with the Met/Met genotype had the lowest Y-BOCS scores. Our data suggest that the COMT high-activity Val allele is associated with more obsessive-compulsive symptoms in young patients with schizophrenia. These results support the hypothesis that the COMT Val(158)Met polymorphism may be a modifier gene for the symptomatology of schizophrenia.